← Latest news 
Cipla bets on inhaled insulin Afrezza to win diabetes patients from injections
Business
Published on 24 April 2026
A mouth inhaler could replace daily injections, but uptake is the test
Cipla is moving forward with the sale of Afrezza, an insulin patients inhale from the mouth, aiming to offer a painless alternative to injectable insulin. The big question is whether this inhaled option can gain traction against entrenched global players and established injection-based routines in diabetes care.
- Cipla plans to sell Afrezza inhaled insulin as an injection alternative
- The company is trying to break into a market dominated by injectable insulin makers
- Success will hinge on patient adoption and real-world usability
- Inhaled insulin could reshape convenience and adherence in diabetes treatment
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times